Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins

Oncogene

Volumn 23, Issue 25, 2004, Pages 4400-4412

  Knockaert, Marie ^a   Blondel, Marc ^a   Bach, Stéphane ^a   Leost, Maryse ^a   Elbi, Cem ^b   Hager, Gordon L ^b   Nagy, Scott R ^c   Han, Dalho ^c   Denison, Michael ^c   Ffrench, Martine ^d   Ryan, Xiaozhou P ^e   Magiatis, Prokopios ^f   Polychronopoulos, Panos ^f   Greengard, Paul ^e   Skaltsounis, Leandros ^f   Meijer, Laurent ^a,e  

^a Protein Phosphorylation and Human Disease Group   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITÉ LYON 1   (France)

^e ROCKEFELLER UNIVERSITY   (United States)

^f UNIVERSITY OF ATHENS   (Greece)

Author keywords

Aryl hydrocarbon receptor; Cancer; Cyclin dependent kinase; Glycogen synthase kinase; GSK 3 ; Indirubin; Kinase inhibitor

Indexed keywords

AROMATIC HYDROCARBON; AROMATIC HYDROCARBON RECEPTOR; CYCLIN DEPENDENT KINASE; DIOXIN; INDIRUBIN; PROTEIN P27; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GROWTH INHIBITOR; INDOLE DERIVATIVE; LIGAND; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL COUNT; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CELL CYCLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; PROTEIN BINDING; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; GROWTH INHIBITORS; HUMANS; INDOLES; LIGANDS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, ARYL HYDROCARBON; STRUCTURE-ACTIVITY RELATIONSHIP; TETRACHLORODIBENZODIOXIN; TUMOR SUPPRESSOR PROTEINS;

EID: 3042629590     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207535     Document Type: Article

References (72)

1. Adachi J, Mori Y, Matsui S, Takigami H, Fujino J, Kitagawa H, Miller III CA, Kato T, Saeki K and Matsuda T. (2001). J. Biol. Chem., 276, 31475-31478.
2. Andersson P, McGuire J, Rubio C, Gradin K, Whitelaw ML, Pettersson S, Hanberg A and Poellinger L. (2002). Proc. Natl. Acad. Sci. USA, 99, 9990-9995.
3. Abdelrahim M, Smith III R and Safe S. (2003). Mol. Pharmacol., 63, 1373-1381.
4. Bain J, McLauchlan H, Elliott M and Cohen P. (2003). Biochem. J., 371, 199-204.
5. Balfour-Paul J. (1998). Indigo. British Museum Press: London, UK, 264pp.
6. Bergander L, Wahlstrorn N, Alsberg T, Bergman J, Rannug A and Rannug U. (2003). Drug Metab. Dispos., 31, 233-241.
7. Borgne A and Meijer L. (1996). J. Biol. Chem., 271, 27847-27854.
8. Bradshaw TD, Trapani V, Vasselin DA and Westwell AD. (2002). Curr. Pharm. Design, 8, 2475-2490.
9. Chotani G, Dodge T, Hsu A, Kumar M, LaDuca R, Trimbur D, Weyler W and Sanford K. (2000). Biochim. Biophys. Acta, 1543, 434-455.
10. Cooksey CJ. (2001). Molecules, 6, 736-769.
11. Damiens E, Baratte B, Marie D, Eisenbrand G and Meijer L. (2001). Oncogene, 20, 3786-3797.
12. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA and Noble MEM. (2001). Structure, 9, 389-397.
13. Dealler SF, Hawkey PM and Millar MR. (1988). J. Clin. Microbiol., 26, 2152-2156.
14. Denison MS,, Phelen D and Elferink CJ. (1998). Xenobiotics, Receptors and Gene Expression. Denison MS and Helferich W (eds). Taylor & Francis: Philadelphia, PA, pp. 3-33.
15. Denison MS and Nagy SR. (2003). Annu. Rev. Pharmacol. Toxicol., 43, 309-334.
16. Elbi C, Misteli T and Hager GL. (2002). Mol. Biol. Cell, 13, 2001-2015.
17. Elferink CJ. (2003). Cell cycle regulators as therapeutic targets. Meijer L, Jezequel A and Roberge M (eds). Progr. Cell Cycle Res., 5, 261-267.
18. Elferink CJ, Ge NL and Levine A. (2001). Mol. Pharmacol., 59, 664-673.
19. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert D, Rudikoff S, Ward JM and Gonzalez FJ. (1995). Science, 268, 722-726.
20. Ffrench M, Bryon PA, Fière D, Vu Van H, Gentilhomme O, Adeleine P and Viala J-J. (1985). Cytometry, 6, 47-53.
21. Fukunaga BN, Probst MR, Reisz-Porszasz S and Hankinson O. (1995). J. Biol. Chem., 270, 29270-29278.
22. Ge NL and Elferink CJ. (1998). J. Biol. Chem., 273, 22708-22713.
23. Gillam EMJ, Notley LM, Cai H, DeVoss JJ and Guengerich FP. (2000). Biochemistry, 39, 13817-13824.
24. Guthrie C and Fink GR. (1991). Guide to Yeast Genetics and Molecular Biology, Abelson JN and Simon MI (eds). Academic Press Inc.: San Diego, CA, USA.
25. Hahn ME. (2002). Chem.-Biol. Interact., 141, 131-160.
26. Hankinson O. (1995). Annu. Rev. Pharmacol. Toxicol., 35, 307-340.
27. Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T, Kamihira S and Tomonaga M. (2003). Biochem. Biophys. Res. Commun., 300, 128-134.
28. Heath-Pagliuso Rogers WJ, Tullis K, Seidel SD, Cenijn PH, Brouwer A and Denison M. (1998). Biochemistry, 37, 11508-11515.
29. Hoessel R, Leclerc S, Endicott J, Noble M, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G and Meijer L. (1999). Nat. Cell Biol., 1, 60-67.
30. Jacobs MN, Dickins M and Lewis DF. (2003). J. Steroid Biochem. Mol. Biol., 84, 117-132.
31. Jain S, Maltepe E, Lu MM, Simon C and Bradfield CA. (1998). Mech. Dev., 73, 117-123.
32. Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA and Reiners JJ. (2003). Drug Metab. Dispos., 31, 1279-1282.
33. Kawanishi M, Sakamoto M, Ito A, Kishi K and Yagi T. (2003), Mutat. Res., 540, 99-105.
34. Knockaert M, Greengard P and Meijer L. (2002). Trends Pharmacol. Sci., 23, 417-425.
35. Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Buchler MW and Friess H. (2002). Oncogene, 21, 6059-6070.
36. Kolluri SK, Weiss C, Koff A and Göttlicher M. (1999). Genes Dev., 13, 1742-1753.
37. Kolluri SK, Balduf C, Hofmann M and Göttlicher M. (2001). Cancer Res., 61, 8534-8539.
38. Kuchenhoff A, Seliger G, Klonisch T, Tscheudschilsuren G, Kaltwasser P, Seliger E, Buchmann J and Fischer B. (1999). Fertil. Steril., 71, 354-360.
39. Kuramoto N, Baba K, Gion K, Sugiyama C, Taniura H and Yoneda Y. (2003). J. Neurochem., 85, 264-273.
40. Lahvis GP, Lindell SL, Thomas RS, McCuskey RS, Murphy C, Glover E, Bentz M, Southard J and Bradfield CA. (2000). Proc. Natl. Acad. Sci. USA, 97, 10442-10447.
41. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Mandelkow E-M, Eisenbrand G and Meijer L. (2001). J. Biol. Chem., 276, 251-260.
42. Ma Q and Whitlock JP. (1996). Mol Cell Biol., 16, 2144-2150.
43. MacNeil IA, Tiong CL, Minor C, August PR, Grossman TH, Loiacono KA, Lynch BA, Phillips T, Narula S, Sundaramoorthi R, Tyler A, Aldredge T, Long H, Gilman M, Holt D and Osburne MS. (2001). J. Mol. Microbiol. Biotechnol. 3, 301-308.
44. Marko D, Schätzte S, Friedel A, Genzlinger A, Zankl H, Meijer L and Eisenbrand G. (2001). Br. J. Cancer, 84, 283-289.
45. Maugard T, Enaud E, Choisy P and Legoy MD. (2001). Phytochemistry, 58, 897-904.
46. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CD, Brivanlou A, Dajani R, Tarricone A, Musacchio A, Roe SM, Pearl L and Greengard P. (2003). Chem. Biol., 10, 1255-1266.
47. Miller CA. (1997). J. Biol. Chem., 272, 32824-32829.
48. Miller CA. (1999). Toxicol. Appl. Pharmacol., 160, 297-303.
49. Mosmann J. (1983). Immunol. Methods, 65, 55-63.
50. Nagy SR, Sanborn JR, Hammock BD and Denison MS. (2002a). Toxicol. Sci., 65, 200-210.
51. Nagy SR, Liu G, Lam KS and Denison MS. (2002b). Biochemistry, 41, 861-868.
52. Peters WL and Wiley D. (1995). Toxicol. Appl. Pharmacol., 13, 214-221.
53. Petersen SL, Curran MA, Marconi SA, Carpenter CD, Lubbers LS and McAbee MD. (2000). J. Comp. Neurol., 427, 428-439.
54. Polychronopoulos P, Magiatis P, Skaltsounis L, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M, Greengard P and Meijer L. (2004). J. Med. Chem., 47, 935-946.
55. Primot A, Baratte B, Gompel M, Borgne A, Liabeuf S, Romette JL, Costantini F and Meijer L. (2000). Protein Expr. Purif., 20, 394-404.
56. Procopio M, Lahm A, Tramontano A, Bonati L and Pitea D. (2002). Eur. J. Biochem., 269, 13-18.
57. Rannug U, Bramstedt H and Nilsson U. (1992). Mutat. Res., 282, 219-225.
58. Rowlands JG and Gustafsson JA. (1997). Crit. Rev. Toxicol., 27, 109-134.
59. Safe S. (2001). Toxicol. Lett., 120, 1-7.
60. Safe S and McDougal A. (2002). Int. J. Oncol., 20, 1123-1128.
61. Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Coniat M, Ghysdael J, Berger R and Bernard OA. (2000). Proc. Natl. Acad. Sci. USA, 97, 6757-6762.
62. Santini RP, Myrand S, Elferink C and Reiners JJ. (2001). J. Pharmacol. Exp. Ther., 299, 718-728.
63. Schmidt JV, Su GH, Reddy JK, Simon MC and Bradfield CA. (1996). Proc. Natl. Acad. Sci. USA, 93, 6731-6736.
64. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y and Ishikawa T. (2000). Proc. Natl. Acad. Sci. USA, 97, 779-782.
65. Song J, Clagett-Dame M, Peterson RE, Hahn ME, Westler WM, Sicinski RR and DeLuca HF. (2002). Proc. Natl. Acad. Sci. USA, 99, 14694-14699.
66. Spink BC, Hussain HM, Katz BH, Eisele L and Spink DC. (2003). Biochem. Pharmacol., 66, 2313-2321.
67. Tang W and Eisenbrand G. (1992). Chinese Drugs of Plant Origin, Chemistry, Pharmacology, and Use in Traditional and Modern Medicine. Springer-Verlag: Heidelberg.
68. Wei YD, Bergander L, Rannug U and Rannug A. (2000). Arch. Biochem. Biophys., 383, 99-107.
69. Weiss C, Kolluri SK, Kiefer F and Göttlicher M. (1996). Exp. Cell Res., 226, 154-163.
70. Wolff S, Harper PA, Wong JM, Mostert V, Wang Y and Abel J. (2001). Mol. Pharmacol., 59, 716-724.
71. Xiao Z, Hao Y, Liu B and Qian L. (2002). Leukemia Lymphoma, 43, 1763-1768.
72. Yoon BI, Hirabayashi Y, Kawasaki Y, Kodama Y, Kaneko T, Kanno J, Kim DY, Fujii-Kuriyama Y and Inoue T. (2002). Toxicol. Sci., 70, 150-156.